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and 0.2 ml of saline). The following substances were administered 
intragastrically 2 times a day at 7-hour intervals for 30 days start-
ing from the 1st day of EAE induction: anti-S100 (n = 20, 2.5 mL/
kg/d); distilled water (control; n = 20, 5 mL/kg/d). Reference drug 
(Glatiramer acetate, Copaxone®, Teva, Israel, n = 20) was adminis-
tered intramuscularly (4 mg/kg) from the 2nd to the 25th day after 
EAE induction.
Results: The severity of neurologic symptoms was assessed in points: 
muscle weakness, tremor (0.5 point); resistant paresis (1 point); 
paralysis (1.5 points). Clinical Index (CI) was calculated as a sum of 
the symptoms for 4 limbs. CI was defined as zero if visible clinical 
signs were absent, and as 6 in case of animal’s death. Cumulative 
index for each rat was calculated as a sum of individual CI for the 
total disease period (30 days). Time to disease onset (days) and the 
mean severity of the disease (points) were recorded in each group.
The key results of the study are presented in the Table.
Conclusion: Anti-S100 ameliorated clinical symptoms of EAE in 
Wistar rats: they both significantly reduced the severity of the disease 
and delayed the disease onset. The results give promise to patients in 
a search of a treatment option for multiple sclerosis.
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Introduction: In Sweden, some triptans became available over the 
counter (OTC) in 2008. The present study describes the utilization 
pattern of prescribed and OTC triptans in Sweden over time.
Patients (or Materials) and Methods: Wholesaler and aggregated 
sales data from the National Corporation of Swedish Pharmacies 
between 1991 and 2006, and patient identity data on dispensed pre-
scriptions between 2006 and 2010 from the National Prescribed 
Drug Register were used to investigate volume and expenditure of 
triptans over time. Prevalence was calculated for 2007 and 2011, 
measured as the number of patients/1000 inhabitants dispensed at 
least 1 triptan prescription. To illustrate proportions of patients dis-
pensed large and small amounts of the drug, respectively, Lorentz 
percentiles and Lorentz curves were used. Analyses were done by 
age and gender.
Results: Volumes of triptans sold has increased continuously to 
7.0 million defined daily doses (DDD) dispensed on prescriptions 
and 0.7 million DDDs OTCin 2011. The prevalence of triptan uti-
lization was 10.0 in 2007 and increased slightly to 10.1 in 2011. 
A marked gender difference was found with a 3.6 times higher 
prevalence of triptan use in women both years. The mean number of 
DDD increased with 10%, from 67 DDD per patient in 2007 to 74 
DDD per patient in 2011. The median volume per patient increased 
even more, 20%, from 30 DDD per patient in 2007 to 36 DDD 
per patient in 2011. Dispensed triptans were unevenly distributed 
within the population. In 2007, in women, 46% of the volume 
was purchased by 10% of those consuming the largest amounts. 
In men, the corresponding proportion consumed by 10% heavy 
users was 50%.
Conclusion: Triptans OTC has increased since the introduction as 
has the purchases of prescribed triptans. The number of patients 
dispensed triptans on prescription remained stable during the period 
studied even though the volumes increased.
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Introduction: There could be an opportunity for health authorities 
to take advantage of oral generic atypical antipsychotic drugs (AAPs) 
given their considerable expenditure across countries. However, 
schizophrenia and bipolar disorders (BPD) are complex to treat, 
with the need to tailor treatments. Consequently, there is a need to 
assess changes in risperidone utilization before and after oral generic 
risperidone was reimbursed among European countries, as well as 
the utilization of generic versus originator risperidone, to provide 
future guidance.
Patients (or Materials) and Methods: We principally used an inter-
rupted time series design of monthly aggregated AAP utilization 
(2011 DDDs) up to 2 years before generic risperidone became avail-
able and reimbursed and up to 6 years after in Austria, Belgium, 
Ireland (GMS population), Scotland, Spain (Catalonia), and 
Sweden; (ii) Demand-side measures captured and categorised using 
the 4Es (Education, Engineering, Economics and Enforcement). 
Expenditure was also measured. Only administrative databases 
were used.
Results: There were generally no specific measures among the vari-
ous authorities to preferentially encourage the prescribing of oral 
Groups, 
the number 
of animals
Proportion 
of Animals 
With Symp-
toms
Severity of 
Symptoms
Time to Dis-
ease Onset, 
days
Mean 
Cumulative 
CI, Points 
(M ± m)
Mild, % Average, % Severe %
Control,  
n = 20
80 20 25 35 9.5 (8.0–
11.3)
27.53 ± 
7.19
Glatiramer 
acetate,  
n = 20
65 5 40 20 10.0 (9.0–
11.0)
18.03 ± 
6.20
Anti-S100, 
n = 20
85 40 40 5* 12.0 (8.0–
14.0)
18.96 ± 
5.94
⁎The difference with control is significant at P < 0.05 (chi-square test).
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generic risperidone, although there were prescribing restrictions 
for long-acting injectable risperidone in Austria and Belgium. As a 
result, no change in its utilization after generics reimbursed. Overall, 
high utilization of generic versus originator risperidone once avail-
able. Appreciable reduction in the price of generic risperidone once 
it became available limited the extent of any subsequent increase in 
AAP expenditure despite increasing utilization.
Conclusion: No apparent effectiveness or safety problems with 
generic risperidone. Authorities cannot rely on a spillover effect from 
other disease areas to change physician prescribing habits, exacer-
bated on this occasion by the need to tailor treatment approaches 
with different AAPs having different mechanisms of action and 
appreciable variability in their effectiveness and side-effects between 
patients Consequently, specific demand-side measures are needed to 
encourage the prescribing of generic AAPs first line where appropri-
ate, exacerbated by the complexity of these disease areas. Likely 
in any event that there will be limited influence of any measures 
in changing subsequent physician prescribing habits when manag-
ing patients with schizophrenia or BPD compared with acid-related 
stomach disorders or hypercholesterolemia as a greater need to tailor 
treatments. Generally no specific measures planned by these authori-
ties to influence future prescribing habits with further generic AAPs 
becoming available.
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Introduction: Antidepressive drug venlafaxine belongs to the seroto-
nine and norepinephrine reuptake inhibitors. It is primary metabo-
lized by CYP2D6 to its active metabolite O-desmethylvenlafaxine 
and by CYP3A4 to N-desmethylvenlafaxine. The range 0.3-5.2 for 
O-desmethylvenlafaxine/venlafaxine ratio was estimated for exten-
sive and intermediate metabolizers.
Patients (or Materials) and Methods: There is described intoxication 
of woman (41 years) treated by combination therapy venlafaxine 
150 mg/d, mianserine 60 mg/d, clonazepam 1 mg/d, and olanzapine 
10 mg/d. TDM of these substances was provided using LC-MS/MS 
method to estimate phenotype of venlafaxine and to compare with 
genotype.
Results: On admission, toxic plasma level of venlafaxine was 
found (2638 ng/mL) and after reduction of the dose to 75 mg/d 
plasma level was estimated in therapeutic range (364 ng/mL). The 
ratio O-desmethylvenlafaxine/venlafaxine was estimated between 
0.005 and 0.016 showing poor metabolizator. Genetic examina-
tion detected homozygotes deletion of the gene CYP2D6 *5/*5 
and explained phenotype. Plasma level of olanazapine was found 
in therapeutic range, plasma level of clonazepam was found below 
therapeutic range.
Conclusion: The ratio of the metabolite to the parent substance (phe-
notype) allows us to detect any deviation in the metabolism of drugs 
which can be subsequently explained by determination of genotype. 
Therapeutic drug monitoring contributes to the optimalization of 
pharmacotherapy in the case of psychotropic drugs.
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Introduction: Alzheimer’s disease is a neurodegenerative disorder 
associated with depletion of acetylcholine in neuronal terminals with 
increased oxidative stress in cells resulting in neuroinflammation. 
Inhibiting acetylcholine esterase (AchE) increases the concentration of 
neuronal acetylcholine. Further xanthine oxidase (XO) is an important 
source of free radicals and plays an important role in oxidative stress 
associated with neuroinflammation. Thus, a dual acting inhibitor of 
AchE & XO can be a good candidate for the treatment of neurodegen-
erative disorders like Alzheimer’s. The aim of this study is to explore the 
inhibitory potential of 4-methyl esculetin against both AchE and XO.
Patients (or Materials) and Methods: The X-ray crystal structures of 
rivastigmine bound to acetylcholinesterase (AChE) (PDB 1GQR) and 
quercetin bound to xanthine oxidase (XO) (PBD 3NVY) were obtained 
from the Protein Data Bank. The proteins were prepared for the dock-
ing studies with the Protein Preparation Wizard in the Schrödinger Suite 
2012 (Schrödinger LLC, USA). The ligand 4-methyl esculetin (4-ME) 
was docked into the target proteins AhcE and XO and binding poses 
ranked by Glide Score (SP). The inhibitory activity of 4-ME towards 
AchE was measured by an in vitro assay using rat brain AchE, and inhi-
bition of XO was done using crude XO obtained from rat liver tissue.
Results: The docking studies revealed that 4-methyl esculetin binds 
in a similar fashion to both AChE and XO and makes identical inter-
actions as the native ligands (rivastigmine for AchE & quercetin for 
XO). The Glide Score for 4-methyl esculetin (–6.97 for AchE and 
–7.78 for XO) also does not differ significantly in both targets; hence, 
it can be said with confidence that 4-ME should exhibit comparable 
potency towards the 2 protein targets. This is well substantiated by 
in vitro enzyme assays that confirmed the equal inhibitory properties 
of 4-ME towards both the target viz. AchE and XO. Kinetic studies 
showed that 4-ME acts as a competitive inhibitor against XO while 
exhibiting mixed type inhibition toward AchE.
Conclusion: The results of the present study indicate that a combi-
nation of both AchE and XO inhibitory properties for 4-ME could 
make it a useful asset in the management of Alzheimer’s disease.
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Introduction: Aluminium is a potent neurotoxin and has been associ-
ated with Alzheimer’s disease (AD). Prolonged aluminium exposure 
induces oxidative stress and contributes to the development of neu-
rodegeneration. Current treatment modalities for AD provide only 
symptomatic relief, thus necessitating the development of new drugs 
with multiple targeting strategies. The aim of the study was to dem-
onstrate the protective effect of chronic administration of 4-methyl-
esculetin (4-ME) against aluminium-induced cognitive dysfunction 
and oxidative damage in rats.
Patients (or Materials) and Methods: Wistar rats (180–200 g) were 
divided into 6 groups (n = 6). Group I was the control group and 
group II received aluminium chloride (100 mg/kg PO) for a period 
of 42 days. Group III and IV received 4-ME (50 and 100 mg/kg PO) 
daily 1 hour before aluminium chloride (100 mg/kg PO) for 42 days 
while groups V and VI received only 4-ME (50 and 100 mg/kg PO) 
daily for 42 days. On the 21st and 42nd day, behavioral studies 
